Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | COM503 |
| Synonyms | |
| Therapy Description |
COM503 is an antibody that targets IL18BP and decreases binding to IL-18, which potentially enhances antitumor immune response (Journal for ImmunoTherapy of Cancer 2023;11). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| COM503 | COM-503|COM 503 | COM503 is an antibody that targets IL18BP and decreases binding to IL-18, which potentially enhances antitumor immune response (Journal for ImmunoTherapy of Cancer 2023;11). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06759649 | Phase I | COM503 + Zimberelimab COM503 | A Clinical Trial to Assess COM503 in Participants with Advanced Solid Malignancies | Recruiting | USA | ISR | 0 |